Form 4: Halozyme Therapeutics SVP, Chief Technical Officer Michael J. LaBarre Reports Stock Transactions
SEC Form 4
Michael J. LaBarre, SVP, Chief Technical Officer of Halozyme Therapeutics, reports exercising stock options and selling shares under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On March 12 and 13, 2024, Michael J. LaBarre, SVP, Chief Technical Officer of Halozyme Therapeutics, executed transactions involving the company's common stock.
- LaBarre exercised options to purchase 10,000 shares at $12.07 on March 12 and sold 10,000 shares at a weighted average price of $41.637.
- On March 13, LaBarre exercised options to purchase 6,449 shares at $12.07 and 3,551 shares at $8.11.
- He then sold 10,000 shares at a weighted average price of $42.273.
- These transactions were conducted under a Rule 10b5-1 trading plan adopted on March 9, 2023.
- Following these transactions, LaBarre directly owns 156,558 shares of common stock and holds options to purchase 87,926 shares.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies. Monitoring these transactions can provide insights into management's perspective on the company's value and future prospects. Rule 10b5-1 plans are frequently used to allow insiders to sell shares without being accused of trading on non-public information.
Comparison to Industry Standards
- Executive compensation packages often include stock options as a way to align management's interests with those of shareholders.
- The vesting schedules and exercise prices of these options are typically benchmarked against industry standards to attract and retain talent.
- Sales under 10b5-1 plans are common and allow insiders to diversify their holdings over time.
- Comparing the volume and frequency of insider transactions at Halozyme to those of its peers (e.g., companies like argenx, BioMarin Pharmaceutical, or Vertex Pharmaceuticals) can provide a broader context for assessing the significance of these transactions.
Stakeholder Impact
- The transactions may have a minor impact on shareholders, potentially influencing the stock price in the short term.
- The transactions do not appear to have a direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 02/03/2016 | Date of option grant for 3,551 shares, vesting one-fourth on the first anniversary and then 1/48th monthly thereafter. |
| 02/22/2017 | Date of option grant for 10,000 shares, vesting one-fourth on the first anniversary and then 1/48th monthly thereafter. |
| 03/09/2023 | Date the Rule 10b5-1 trading plan was adopted by the Reporting Person. |
| 03/12/2024 | Date of option exercise and stock sale. |
| 03/13/2024 | Date of option exercise and stock sale. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.